L-Trizin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of L-Trizin

What is L-Trizin? (Overview)

The pharmaceutical product L-Trizin contains the active ingredient Levocetirizine Dihydrochloride, a synthetic medication utilized for managing the discomfort associated with allergic responses. This agent is classified as a second-generation antihistamine, acting as a highly selective peripheral H₁-receptor antagonist.


Quick Facts: L-Trizin

Property Description
Active Ingredient Levocetirizine Dihydrochloride
Form Oral tablet, Oral solution
Pharmacological Class H₁-receptor Antagonist
Common Use Relief of general allergic symptoms
Origin Synthetic; R-enantiomer of Cetirizine

What is L-Trizin and its Pharmacological Class?

L-Trizin is a highly selective second-generation antihistamine that belongs to the pharmacological class of H₁-receptor antagonists. The active component, Levocetirizine Dihydrochloride, is chemically the highly active R-enantiomer (a specific molecular structure) of the related compound, cetirizine, from which it is derived. This makes Levocetirizine a potent metabolite and a member of the piperazine class. Its high specificity for the peripheral H₁ receptor means it primarily blocks the chemical mediator histamine where it causes immediate symptoms. This focused action of the synthetic compound is clinically recognized for providing targeted anti-allergic effects.

What are the General Benefits of Levocetirizine?

The primary benefit of Levocetirizine is to provide prompt systemic relief from the discomfort associated with allergic responses. By acting as a selective H₁-receptor antagonist, L-Trizin prevents histamine from binding to its receptors, thereby neutralizing the initial inflammatory cascade triggered by the body’s overreaction to allergens. Levocetirizine is an effective anti-allergic agent. This targeted mechanism helps to mitigate common physiological manifestations, such as persistent itching, watery eyes, and sneezing, offering relief in typical scenarios like seasonal allergy exposure.

What Form is L-Trizin Available In?

L-Trizin is a single-ingredient product formulated for oral administration, typically available as an oral tablet and an oral solution. These dosage forms, including the solid oral tablet and the liquid oral solution, allow for the systemic absorption of the active ingredient. The liquid formulation is often positioned for pediatric patients or those who require an easier-to-swallow form. The active substance is combined with either solid excipients or an aqueous vehicle, confirming its identity as a versatile oral preparation.

Regulatory References

  1. Public Assessment Report (NL Agency)

What side effects are possible with L-Trizin?

Official Adverse Reactions and Safety Profile

The safety profile of L-Trizin (Levocetirizine Dihydrochloride) is categorized by regulatory authorities based on the frequency and the physiological system affected. The data reflect findings from clinical trials and post-marketing surveillance, as documented in official government labeling.

Frequency Classification

Adverse reactions are classified into frequency tiers, reflecting their documented occurrence rates. Common reactions (occurring in ge1/100 to <1/10 individuals) include somnolence (drowsiness), dry mouth, fatigue, and headache. Uncommon reactions (occurring in ge1/1,000 to <1/100) include asthenia and abdominal pain. A wide range of events are categorized as Not Known frequency, meaning their occurrence rate cannot be estimated from available post-marketing data, but are officially listed.

System-Organ Classes and Serious Events

Side effects documented in regulatory sources span multiple system-organ classes, including Nervous system disorders (e.g., somnolence, dizziness, convulsion), Gastrointestinal disorders (e.g., dry mouth, nausea), and Skin and subcutaneous tissue disorders (e.g., pruritus, rash). Serious adverse reactions reported under the Not Known frequency classification include hypersensitivity reactions, such as anaphylaxis, as well as convulsion and suicidal ideation.

Specific Safety Considerations

The official labeling includes specific restrictions regarding patient health status. The medicine is contraindicated in individuals with severe renal impairment (creatinine clearance <10 mL/min) or those undergoing hemodialysis. Caution is advised in patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia) and in patients with epilepsy or those at risk of convulsions. Additionally, the label notes that severe pruritus (itching) has been reported following discontinuation after long-term, daily use.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes the officially documented overdose information and mandated emergency actions for Levocetirizine Dihydrochloride (L-Trizin), strictly based on government regulatory sources.


Documented Overdose Manifestations

The clinical signs of overdose are typically an extension of the known central nervous system (CNS) effects. The primary manifestation documented in adults is somnolence (drowsiness). In pediatric patients, the presentation differs, often involving initial agitation followed by the onset of somnolence.

Other officially documented manifestations include tachycardia (increased heart rate), tremor, confusion, headache, mydriasis (dilated pupils), diarrhea, and urinary retention. These effects reflect documented impact on the CNS and systemic functions.


Emergency Actions and Management

In the event of a known or suspected overdose, immediate medical attention must be sought. Official regulatory guidance mandates that emergency services or a poison control center be contacted immediately.

The official treatment protocol is symptomatic and supportive, focused on managing the clinical signs and sustaining vital functions. No specific antidote is known for Levocetirizine overdose. Furthermore, regulatory information states that dialysis, including hemodialysis, is considered ineffective for drug removal. Depending on the clinical assessment, procedures such as gastric lavage or administration of activated charcoal may be considered.

Therapeutic Uses of L-Trizin

What L-Trizin Treats: Main Uses and Benefits

L-Trizin is generally applied across domains where additional symptomatic support is needed. The medication is commonly used to help with symptoms related to physical discomfort that create noticeable physiological strain, primarily assisting in easing the overall symptom load.


Easing Episodic Symptomatic Discomfort

L-Trizin is commonly used across conditions involving episodic or fluctuating manifestations. It is relevant for managing symptoms associated with inflammatory or irritative states. The medicine helps address symptom clusters that may appear suddenly or intensify temporarily, providing supportive relief that may help patients cope more steadily with symptom fluctuations.


Supportive Management of Functional Strain

This medicine is relevant for conditions presenting with systemic or localized discomfort associated with acute or disruptive episodes. It is applied when symptoms interfere with daily comfort. L-Trizin assists with maintaining functional stability. It is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed.

Quick Fact: Used for Symptoms that Interfere with Daily Functioning.

Eligibility and Restrictions for Use

Who can and cannot use L-Trizin?

Regulatory documents establish specific rules regarding who is eligible to use L-Trizin (levocetirizine) and who must avoid it. The most critical restriction is the formal contraindication against its use in certain populations.


Population Category Eligibility Status (Official Regulatory Statement)
Known Hypersensitivity Contraindicated in patients with a known hypersensitivity to the active substance, cetirizine, hydroxyzine, or other piperazine derivatives.
End-Stage Renal Disease (Adults/Adolescents ge 12 years) Contraindicated in patients with end-stage renal disease (creatinine clearance <10 mL/min) or those undergoing hemodialysis.
Pediatric Patients with Renal Impairment (6 months to 11 years) Contraindicated with any degree of renal impairment in this age group.
Age Restriction Safety and efficacy are not established for use in infants younger than 6 months of age.

Use of L-Trizin is allowed for adults and children starting at 6 months of age, provided they meet the established criteria. For patients 12 years and older with mild, moderate, or severe kidney impairment, use is restricted and requires a dose adjustment based on the degree of renal function. No dose adjustment is specified for isolated hepatic impairment. Additionally, use should be approached with caution in patients with factors predisposing them to urinary retention, such as prostatic hyperplasia or spinal cord lesions.

What should I know about interactions with other medicines?

L-Trizin Interactions with other medicines and products

This section details officially documented interaction information for L-Trizin (Levocetirizine Dihydrochloride) as described in authoritative government regulatory sources.


Pharmacodynamic Interactions

Interacting Substance Official Effect Description
Alcohol (Ethanol) Potential for additive reductions in alertness and further impairment of Central Nervous System (CNS) performance.
CNS Depressants (e.g., Sedatives, Tranquilizers) Potential for additive reductions in alertness and impairment of CNS performance.

Pharmacokinetic and Clearance-Altering Interactions

L-Trizin is minimally metabolized. Studies on the racemate, cetirizine, are cited in regulatory documents concerning altered clearance.

  • Ritonavir: Documented to increase the systemic plasma exposure (AUC) of the active substance (cetirizine) by approximately 42% and decrease its total body clearance by 29%.
  • Theophylline: Documented to cause a small decrease (around 16%) in the clearance of the active substance (cetirizine).

Food and Population-Specific Considerations

Context Regulatory Statement
Food Does not reduce the total extent of absorption, but slows the rate of absorption of L-Trizin.
Renal Impairment Patients are at risk of increased systemic exposure due to impaired clearance, as the drug is substantially excreted via the kidneys.

No formal drug-drug combinations are listed as contraindicated. No mandatory time separation requirements for co-administration are documented in the official labeling.

Mechanism of Action

How L-Trizin Works

L-Trizin (Levocetirizine Dihydrochloride) functions primarily through selective competitive antagonism at the peripheral Histamine H₁ receptor. This molecular blockade prevents the binding of endogenous histamine, thereby interrupting the initiation of the acute allergic signaling cascade. This action results in reduced plasma extravasation across the vascular endothelium and decreased signaling from peripheral sensory nerves.

Beyond H₁ receptor engagement, a secondary mechanism involves the inhibition of eosinophil migration and the suppression of pro-inflammatory mediator release, including chemokines (e.g., eotaxin) and specific interleukins. This secondary action modulates the cellular component of the inflammatory response.

The drug's molecular structure confers limited access across the Blood-Brain Barrier (BBB). By restricting its activity to the periphery, L-Trizin maintains high receptor occupancy in targeted tissues. This structural constraint results in minimal engagement of central H₁ receptors.

Dosage and Administration Information

How to Use L-Trizin

L-Trizin, which contains Levocetirizine Dihydrochloride, is strictly administered via the oral route as either an oral tablet or an oral solution. The usage pattern is a once-daily (QD) schedule, with administration typically recommended in the evening.

Standard Dosing and Administration

The standard prescribed dose for adults and adolescents 12 years of age and older is 5 mg taken once daily. This 5 mg maximum daily dose must not be exceeded. For children aged 6 to 11 years, the official dose is 2.5 mg once daily. The oral tablet is scored to allow for breaking, which facilitates the administration of the 2.5 mg dose. The liquid oral solution is used for the lowest prescribed dose of 1.25 mg once daily for pediatric patients aged 6 months to 5 years.

Contextual Use Instructions

L-Trizin may be consumed with or without food, as food intake does not alter the systemic absorption of the active ingredient. The medicine is used for both short-term symptomatic relief and as part of long-term maintenance plans for chronic conditions, such as Perennial Allergic Rhinitis.

Population-Specific Dose Adjustments

Dosing must be modified for adult patients (12 years and older) who have impaired renal function. The dose is reduced based on the degree of kidney function, as determined by Creatinine Clearance (CLCR). For example, moderate impairment (CLCR = 30-50 mL/min) requires a reduced dose of 2.5 mg once every other day. No dose adjustment is specified for patients with isolated hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for L-Trizin


Evidence for use in Seasonal Allergic Rhinitis (SAR)

L-Trizin was studied for Seasonal Allergic Rhinitis (SAR) symptoms primarily through short-term, randomized controlled trials (RCTs). These studies were generally applied in research contexts involving fluctuating or unstable symptoms in populations of adults, adolescents, and children (aged 2 years and older). The RCTs compared the medicine against a placebo or against active comparators.

The trials monitored how symptom scores evolved in the observed populations when compared to a placebo or comparator, using scales like the Total 5 Symptom Score. Research also explored patient-reported outcomes describing perceived discomfort and daily functioning or activity level; studies reported measurements for these factors alongside symptom intensity metrics. These findings describe patterns observed in the studies over the course of the research.


Evidence for use in Perennial Allergic Rhinitis (PAR)

Research examined L-Trizin's use in Perennial Allergic Rhinitis (PAR), a condition characterized by persistent, year-round symptoms. The study base here includes some intermediate- to long-term randomized trials that observed responses over defined time intervals, sometimes lasting up to six months. The research describes how measurements of symptom intensity or variability evolved across the full observation period.


Evidence for use in Chronic Idiopathic Urticaria (CIU)

L-Trizin was studied for the uncomplicated skin manifestations of Chronic Idiopathic Urticaria (CIU), involving hives and itching with an unknown cause. This research included short-term randomized trials that typically lasted around four to six weeks. The studies monitored changes in patient-reported outcomes describing perceived discomfort, specifically itching severity, as well as objective assessments of wheal (hives) count and size.


Long-Term Studies and Maintenance Follow-up

Research has explored whether L-Trizin may be relevant in the long-term study of symptom patterns. While some studies was observed in over a period up to six months, long-term effects are not fully established beyond this period. Evidence contributes to understanding symptom patterns over the intermediate term, but there is limited information for long-term outcomes related to the durability of response.


What is Still Uncertain about L-Trizin Research

The overall evidence landscape has limitations. For instance, follow-up durations were limited in many core studies. Long-term effects are not fully established, and there is limited information for long-term outcomes in any patient group. Furthermore, evidence quality varies across studies. For example, findings were mixed in some specific trials, particularly when studies examined L-Trizin compared with placebo.

Key Studies & References Clinical Guideline: Management of Allergic Rhinitis and its Impact on Asthma (ARIA)

Frequently Asked Questions (FAQ)

Common questions about L-Trizin (FAQ)


Q: Can I use L-Trizin while I am pregnant or breastfeeding?

Official regulatory documents indicate that L-Trizin should only be used during pregnancy if it is clearly needed, and consulting a healthcare professional is generally advised. For breastfeeding, the medicine is expected to pass into human milk, and its use is generally discouraged.


Q: What should I do if I miss a dose of L-Trizin?

Official patient directions state that a missed dose may be taken as soon as it is realized. However, if it is nearly time for the next scheduled dose, the general guidance is to skip the missed dose. Taking a double amount to compensate for a missed dose is not advised.


Q: How long does L-Trizin take to start working?

Official product information shows that L-Trizin is absorbed quickly after oral administration. Studies indicate that the concentration of the active ingredient reaches its peak level in the blood in less than an hour for the oral solution, and in approximately one hour for the tablet.


Q: Can I take L-Trizin with a sedating pain medicine?

Official warnings state that L-Trizin may cause drowsiness. Taking it alongside other central nervous system (CNS) depressants, such as certain sedating pain medicines, tranquilizers, or alcohol, may increase this drowsiness. Regulatory warnings indicate that caution is necessary when combining L-Trizin with other medicines that cause sedation.


Q: What are the symptoms of an L-Trizin overdose?

According to the official prescribing information on overdose, symptoms can vary slightly by age. In adults, an overdose is primarily associated with somnolence (drowsiness). In children, an overdose may be marked by a period of agitation or restlessness before the onset of drowsiness.


Q: Can L-Trizin be split in half if the tablet is scored?

Yes, the 5 mg oral tablet is manufactured as a scored tablet, which is designed to allow it to be broken. Official labeling notes that this feature facilitates the administration of the 2.5 mg dose that is specified for children.


Q: What should I do if I experience severe itching after stopping L-Trizin?

Official drug safety communications have reported cases of severe itching (pruritus) after patients stop taking L-Trizin daily for a long period. If this is experienced upon discontinuation, consulting a healthcare professional for guidance is important.

How should L-Trizin be stored and disposed of?

How to Store and Dispose of L-Trizin (Levocetirizine Dihydrochloride)

L-Trizin must be stored according to official regulatory requirements to maintain product stability and safety. The medication must be kept at Controlled Room Temperature, defined as a range between 20 C and 25 C (68 F and 77 F). The product must remain in its original container and be protected from moisture. The label mandates that L-Trizin be stored out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused L-Trizin should be disposed of via a drug take-back program. If this is not available, official guidance instructs mixing the medicine with an unpalatable substance (like dirt or coffee grounds) and sealing the mixture in a container before discarding it into the household trash. Do not use the product past its expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of L-Trizin found in:

A-Z Index: